Quantumzyme Corp. (OTC: QTZM), a biotransformation company focused on sustainable enzyme-based solutions, announced continued progress on strategic initiatives including a planned 4-for-1 forward stock split and the advancement of its corporate name change to Quantum Genesis AI Corp. These moves are designed to better align the company's public market profile with its long-term strategic direction.
The Board of Directors has authorized a 4-for-1 forward stock split of issued and outstanding common stock. The forward split is intended to enhance the company's public market profile by recalibrating its capital structure, facilitating greater flexibility in outstanding share structure, supporting administrative efficiency in trading, and aligning the public share profile with its current stage of development. The forward split will be submitted for processing only after completion of the pending corporate name and trading symbol change.
Quantumzyme is in the final stages of completing a corporate name change to Quantum Genesis AI Corp., a change that reflects the company's strategic focus on advancing enzyme innovation through artificial intelligence, computational modeling, and data-driven research. The company anticipates the name and corresponding trading symbol change will be completed in the near term. Immediately following effectiveness of the new name and symbol, Quantumzyme intends to submit the forward stock split to the Financial Industry Regulatory Authority (FINRA) in accordance with applicable regulatory requirements.
President Naveen Kulkarni stated, “Our planned corporate rebranding and capital structure initiatives are intended to better align the Company’s public market profile with its long-term strategic direction. Completing the name and symbol change first establishes a clear foundation, and, subject to regulatory review, the proposed forward stock split is designed to support a more efficient and accessible public share structure as we continue executing on our technology and operational roadmap.”
If approved, the forward stock split will increase the number of outstanding shares while proportionally adjusting the per-share trading price. The company believes this action may provide several potential benefits going forward, including increased flexibility to support future corporate initiatives. The company emphasizes that the forward split is not intended to, and will not by itself, change the overall market capitalization.
The forward stock split will not affect the proportional ownership interests of existing shareholders, except for minor adjustments from fractional share treatment. The company expects to provide additional updates regarding the effectiveness of the corporate name and symbol change, as well as the timing and status of the forward stock split submission and review process, through subsequent public disclosures.
For more information and updates, please visit www.quantumzymecorp.com and the company's profile at www.otcmarkets.com/stock/QTZM.
